Go Pro

Weiss Ratings' Rating of BR Biopharma on 5/22/2026

On May 22, 2026, Weiss Ratings updated its outlook on BR Biopharma (NASDAQ:BRBI) with the action "Downgrade", setting a "Sell (E)" rating. MarketBeat All Access subscribers can view the full ratings details, 12-month ROI, historical price target changes, and related news coverage on this page.

unlock icon  Upgrade to MarketBeat All Access

This premium research tool is available to MarketBeat All Access subscribers only. Log in to your account or sign up below.

Already have an account? Log in here.

More Ratings from Weiss Ratings

DateCompanyAction
8/3/2026
ZOOZ Power Ltd. stock logo
ZOOZ
ZOOZ Power
Upgrade
8/3/2026
Wingstop Inc. stock logo
WING
Wingstop
Reiterated Rating
8/3/2026
WesBanco, Inc. stock logo
WSBC
WesBanco
Reiterated Rating
8/3/2026
Vitesse Energy, Inc. stock logo
VTS
Vitesse Energy
Reiterated Rating
8/3/2026
Vistance Networks, Inc. stock logo
VISN
Vistance Networks
Reiterated Rating
8/3/2026
Vision Marine Technologies Inc. stock logo
VMAR
Vision Marine Technologies
Downgrade
More Ratings From Weiss Ratings